1. In Vivo
  2. >>Innovation

BioBytes: IBM Deal Helps Moderna Maintain Cutting-Edge In Tech

 
• By David Wild

Welcome to In Vivo’s new AI-focused blog, BioBytes, providing news and insight on the growing role of artificial intelligence in biopharma. Moderna is teaming up with IBM to integrate quantum computing into its operations. The partnership should accelerate and optimize drug discovery and development while continuing to evolve Moderna's digital-first approach.

Bio Bytes
• Source: Shutterstock

Moderna, Inc. is maintaining its position at the head of the pack of early tech adopters. The mRNA-focused biotech is partnering with IBM to prepare its workforce to integrate quantum computing into operations.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

Deals Shaping The Industry, March 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

From Brain Waves to Better Outcomes: Inside Alto Neuroscience’s Biomarker Strategy

 
• By David Wild

Alto Neuroscience’s CEO, Amit Etkin, believes the company’s biomarker-based approach to psychiatric treatment is the way forward.

Merck’s Digital Biomarker Strategy For Commercial Gains In Neurology

 
• By Jo Shorthouse

The integration of digital health tools into clinical research and patient care is gaining momentum, and Merck KGaA, Darmstadt, Germany is not letting the grass grow under its feet. With an approach to digital biomarkers, the company is seeking to redefine how neurological diseases are monitored and managed.